Aptar Pharma has announced the selection of a customized Landmark dose indicator for Skyepharma’s Flutiform fluticasone propionate/formoterol fumarate MDI. Flutiform is available for the treatment of asthma in Germany, the UK, and several other countries.
The dose indicator on the Flutiform MDI is based on Aptar’s Landmark platform, which was the winner of a 2007 international award from the FEA (European Aerosol Federation). The Flutiform metering valve is based on Aptar’s DF30 valve platform.
Aptar Pharma Prescription Division VP of Marketing and Communication Pierre Carlotti said, “SkyePharma is a key client for Aptar Pharma. We are particularly proud to have developed the customized versions of Landmark and metering valve for Flutiform.”
Skyepharma CEO Peter Grant commented, “We are pleased with the results of our collaboration with Aptar Pharma, who understood perfectly what we required, and developed the customized Landmark dose indicating actuator and metering valve, key components of Flutiform.”
Read the Aptar press release.
